Fox Run Management L.L.C. Takes $364,000 Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Fox Run Management L.L.C. purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 49,651 shares of the company’s stock, valued at approximately $364,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp raised its position in shares of Vir Biotechnology by 10.4% in the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company’s stock valued at $42,135,000 after purchasing an additional 530,645 shares in the last quarter. Alta Partners Management Company L.P. acquired a new stake in Vir Biotechnology in the fourth quarter valued at $3,593,000. abrdn plc bought a new position in Vir Biotechnology during the 4th quarter valued at $2,666,000. Charles Schwab Investment Management Inc. grew its holdings in Vir Biotechnology by 13.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock worth $8,496,000 after acquiring an additional 136,087 shares in the last quarter. Finally, PDT Partners LLC increased its position in shares of Vir Biotechnology by 34.4% in the 3rd quarter. PDT Partners LLC now owns 220,821 shares of the company’s stock worth $1,654,000 after purchasing an additional 56,494 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Transactions at Vir Biotechnology

In related news, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the transaction, the director now directly owns 708,295 shares of the company’s stock, valued at $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Verneuil Vanina De sold 7,373 shares of the company’s stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the sale, the executive vice president now directly owns 79,460 shares of the company’s stock, valued at $726,264.40. The trade was a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,859 shares of company stock valued at $326,458. 15.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research report on Friday, February 28th. Leerink Partners increased their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Barclays boosted their price target on Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $10.00 to $20.00 in a research note on Thursday, January 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Vir Biotechnology in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.67.

Vir Biotechnology Trading Down 5.2 %

Shares of NASDAQ VIR opened at $6.59 on Thursday. Vir Biotechnology, Inc. has a 12-month low of $6.53 and a 12-month high of $14.45. The company has a market cap of $903.77 million, a price-to-earnings ratio of -1.68 and a beta of 1.17. The stock’s 50 day simple moving average is $8.94 and its 200 day simple moving average is $8.37.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The company had revenue of $12.37 million for the quarter, compared to analysts’ expectations of $8.14 million. As a group, equities analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).